Pair Name	Brusatol, Gemcitabine
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	ABCB1	hsa5243
	Down-regulation	Expression	ABCC1	hsa4363
	Down-regulation	Expression	ABCC2	hsa1244
	Down-regulation	Expression	ABCC3	hsa8714
	Down-regulation	Expression	ABCC4	KEGG ID N.A.
	Down-regulation	Expression	ABCC5	KEGG ID N.A.
	Down-regulation	Expression	ABCC5	KEGG ID N.A.
	Down-regulation	Expression	HMOX1	hsa3162
	Down-regulation	Expression	NFE2L2	hsa4780
	Down-regulation	Expression	NQO1	hsa1728
	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	PANC-1	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0480
	BxPC-3	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0186
	PaTu 8988s	Pancreatic adenocarcinoma	Homo sapiens (Human)	CVCL_1846
In Vivo Model	PANC-1 cells (4×10⁶) were resuspended in 100 μL PBS and then subcutaneously injected in the right flank of nude mice.
Result	Our results suggest that brusatol is capable of enhancing the antitumour effects of gemcitabine in both pancreatic cancer cells and PANC-1 xenografts via suppressing the Nrf2 pathway.